Shots:
- Novartis announced that the P-III HARBOR study of delpacibart etedesiran (del-desiran) in people with myotonic dystrophy type 1 (DM1) did not meet its 1EP of video hand opening time (vHOT)
- Del-desiran showed evidence of clinical activity in 2EPs and exploratory analyses, while safety findings were generally consistent with previously reported data; Novartis is evaluating the full dataset and will determine the appropriate development path.
- The company continues to advance its AOC neuromuscular pipeline, with US FDA priority review granted for delpacibart zotadirsen in DMD44 and a planned FDA meeting for delpacibart braxlosiran in FSHD based on positive P-I/II biomarker data.
Ref: Novartis | Image: Novartis | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information connect with us at connect@pharmashots.com
